Scarica l'app Stockscreener
38.39
1.82%
-0.71
Dopo l'orario di chiusura:
38.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$39.10
Aprire:
$38.78
Volume 24 ore:
315.19K
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.96B
Reddito:
$307.03M
Utile/perdita netta:
$-99.81M
Rapporto P/E:
-18.55
EPS:
-2.0695
Flusso di cassa netto:
$-27.20M
1 W Prestazione:
-3.03%
1M Prestazione:
-18.35%
6M Prestazione:
-2.44%
1 anno Prestazione:
+61.23%
Intervallo 1D:
$38.22
$39.87
Intervallo di 1 settimana:
$37.83
$40.32
Portata 52W:
$23.14
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
38.39 | 1.96B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
LIVMARLI Now Approved In Japan For ALGS And PFIC - MarketScreener
LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe - Nasdaq
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock By Investing.com - Investing.com Australia
Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth - insights.citeline.com
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals president sells $348k in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock - Investing.com
Mirum Pharmaceuticals’ SVP Jolanda Howe sells $2.4 million in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals director Heron buys $24,214 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals director Heron buys $24,214 in stock - Investing.com India
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock - Investing.com India
Mirum Pharmaceuticals director Heron buys $99,517 in stock - Investing.com India
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $99,517 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Leerink Conference: Growth in Rare Diseases By Investing.com - Investing.com Canada
(MIRM) Proactive Strategies - Stock Traders Daily
Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan
Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):